RecruitingPhase 2NCT04166006

A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

Studying Soft tissue sarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Principal Investigator
Laura Ridolfi, MD
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
Intervention
Autologous DC vaccine(biological)
Enrollment
51 enrolled
Eligibility
18 years · All sexes
Timeline
2019 – 2031

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04166006 on ClinicalTrials.gov

Other trials for Soft tissue sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Soft tissue sarcoma →

← Back to all trials